Loading...
•
Mar 31, 2021
Arcus Biosciences Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021 and provided operational highlights.
Key Takeaways
Arcus Biosciences reported its Q1 2021 financial results, highlighting a cash balance of $884.9 million and collaboration revenues of $9.5 million. The company is advancing its clinical trials, including the anti-TIGIT program and studies for AB680 and etrumadenant.
Advanced anti-TIGIT portfolio with ARC-7 interim analysis for domvanalimab on track for 2Q21 and first patient dosed with AB308 in combination with zimberelimab.
Presented promising PFS and OS data for etrumadenant in the ≥3L metastatic colorectal cancer setting at AACR.
Initiated the randomized portion of ARC-8 study evaluating AB680 in pancreatic cancer following rapid completion of enrollment of the dose-expansion portion of the study.
Ended the quarter with $885 million of cash and investments.
Forward Guidance
Arcus Biosciences expects its cash, cash equivalents and marketable securities on-hand to be sufficient to fund operations at least through 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...